Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
The in vitro activity of LY146032, a new cyclic lipopeptide antibiotic, was compared with those of vancomycin, teicoplanin, and either oxacillin or ampicillin by determining agar dilution MIC values for 304 clinical gram-positive isolates. LY146032 had superior in vitro activity against oxacillin-resistant staphylococci when compared to vancomycin or teicoplanin. Against oxacillin-sensitive staphylococci, group JK-diphtheroids, streptococci, Listeria monocytogenes and Clostridium difficile, LY146032 was equally or less active than vancomycin, teicoplanin, or the penicillins tested. When tested by macrobroth dilution MIC/MBC, LY146032 showed good bactericidal activity against all organisms with the exception of Clostridium difficile.
D000667:Ampicillin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D003013:Clostridium / Q000187:drug effects; D017576:Daptomycin; D006020:Glycopeptides / Q000494:pharmacology; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008089:Listeria monocytogenes / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D010068:Oxacillin / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D017334:Teicoplanin; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D010455:Peptides; D017334:Teicoplanin; D014640:Vancomycin; D000667:Ampicillin; D017576:Daptomycin; D010068:Oxacillin